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Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis
who achieve a sustained virological response (SVR) have a lower risk of hepatic decompen-
sation and hepatocellular carcinoma (HCC). In this prospective analysis, we compared the
rate of death from any cause or liver transplantation, and of liver-related morbidity and
mortality, after antiviral therapy among patients who achieved SVR, virologic nonrespond-
ers (NR), and those with initial viral clearance but subsequent breakthrough or relapse
(BT/R) in the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis)
Trial. Laboratory and/or clinical outcome data were available for 140 of the 180 patients
who achieved SVR. Patients with nonresponse (NR; n 5 309) or who experienced break-
through or relapse (BT/R; n 5 77) were evaluated every 3 months for 3.5 years and then
every 6 months thereafter. Outcomes included death, liver-related death, liver transplanta-
tion, decompensated liver disease, and HCC. Median follow-up for the SVR, BT/R, and
NR groups of patients was 86, 85, and 79 months, respectively. At 7.5 years, the adjusted
cumulative rate of death/liver transplantation and of liver-related morbidity/mortality in
the SVR group (2.2% and 2.7%, respectively) was significantly lower than that of the NR
group (21.3% and 27.2%, P < 0.001 for both) but not the BT/R group (4.4% and 8.7%).
The adjusted hazard ratio (HR) for time to death/liver transplantation (HR 5 0.17, 95%
confidence interval [CI] 5 0.06-0.46) or development of liver-related morbidity/mortality
(HR 5 0.15, 95% CI5 0.06-0.38) or HCC (HR 5 0.19, 95% CI 5 0.04-0.80) was signif-
icant for SVR compared to NR. Laboratory tests related to liver disease severity improved
following SVR. Conclusion: Patients with advanced chronic hepatitis C who achieved SVR
had a marked reduction in death/liver transplantation, and in liver-related morbidity/mor-
tality, although they remain at risk for HCC. (HEPATOLOGY 2010;52:833-844)
Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BT/R, breakthrough or relapse; CBC, complete blood
count; CI, confidence ratio; Cr, creatinine; HALT-C, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis; HCC, hepatocellular carcinoma; HCV,
hepatitis C virus; HR, hazard ratio; INR, international normalized ratio; NR, nonresponder; RNA, ribonucleic acid; SSDI, social security death index; SVR,
sustained virological response.
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hronic hepatitis C virus (HCV) infection is a
common cause of cirrhosis, hepatocellular
carcinoma (HCC), and liver transplantation.
Follow-up studies of patients who achieved a sustained
virological response (SVR) after antiviral therapy have
demonstrated that the majority of patients continue to
have undetectable serum HCV RNA, improvement in
liver fibrosis, including reversal of cirrhosis, and a reduc-
tion in the incidence of decompensated liver disease and
HCC compared with subjects who did not achieve an
SVR.1-3 These studies notwithstanding, the beneficial
effect of achieving an SVR on the outcome of patients
with advanced chronic hepatitis C remains incompletely
defined because prior studies were retrospective4-7 and
included a small number of patients with cirrhosis2 and a
relatively limited period of follow-up.8 In addition, few
data are available on patients in the United States, because
most of these studies were conducted in Japan or
Europe.4-8 Furthermore, the beneficial effect of interferon
and ribavirin treatment on the outcomes of patients with
advanced hepatitis C who achieved viral clearance during
treatment and who relapsed after discontinuation of treat-
ment has not been established clearly.6
The Hepatitis C Antiviral Long-Term Treatment
Against Cirrhosis (HALT-C) Trial was a multicenter study
involving more than 1000 patients in the United States
with advanced chronic hepatitis C and nonresponse to
previous treatment with interferon-based therapy.9 Dur-
ing the lead-in phase of the HALT-C Trial, 1145 patients
were treated with a combination of pegylated interferon
and ribavirin; of these, 180 achieved SVR. Patients who
did not achieve SVR entered the randomized phase of the
HALT-C Trial and were followed prospectively for the de-
velopment of fibrosis progression, decompensated liver
disease, HCC, and death. The aim of the current study
was to evaluate the effect of achieving SVR on overall
mortality and on liver-related morbidity and mortality in
this large, prospectively followed cohort of patients from
the United States with advanced chronic hepatitis C.
Patients and Methods
HALT-C Trial Design. The design and primary
results of the HALT-C Trial have been reported.9,10
Briefly, patients with chronic hepatitis C meeting the
following criteria were entered into the lead-in phase
of the HALT-C Trial: advanced hepatic fibrosis (Ishak
fibrosis score 3) according to a liver biopsy per-
formed within 12 months prior to enrollment; lack of
SVR to previous treatment for at least 24 weeks with
standard interferon with or without ribavirin; and no
history of hepatic decompensation or HCC. All
patients in the lead-in phase of the HALT-C Trial were
prescribed combination therapy with peginterferon
alfa-2a at 180 lg weekly and weight-based ribavirin at
1000-1200 mg daily for 24 weeks.
Patients with detectable serum HCV RNA at treat-
ment Week 20 were classified as nonresponders (NR),
and combination therapy was discontinued at Week
24. These patients were randomized to either the
maintenance therapy group (90 lg of peginterferon
alfa-2a weekly, without ribavirin) or to no treatment
(control group) for the next 3.5 years.
Patients with undetectable serum HCV RNA at Week
20 were considered responders, were continued on com-
bination therapy for a total duration of 48 weeks, and
were monitored to Week 72 (24 weeks posttreatment) to
determine if they achieved SVR. If, in a Week 20 re-
sponder, HCV RNA became detectable again after
Week 20, either during treatment (breakthrough) or af-
ter cessation of treatment (relapse), the patient was
offered the opportunity to enter the randomized phase
of the trial (the breakthrough/relapse [BT/R] cohort).
After randomization, patients were seen every 3
months for 3.5 years and then every 6 months there-
after for an interval medical history, physical examina-
tion, and laboratory testing to assess for clinical out-
comes and adverse events. Local laboratory tests
included complete blood count, hepatic panel (which
included serum albumin, aspartate aminotransferase
[AST], alanine aminotransferase [ALT], alkaline phos-
phatase, and total bilirubin), creatinine, prothrombin
time/international normalized ratio (INR), and alpha-
fetoprotein (AFP). Quantitative HCV RNA was meas-
ured in a central laboratory at each visit during the
first 3.5 years. Abdominal ultrasound was performed 6
months after randomization and then every 12 months
to screen for HCC.
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Design of the Current Study. According to the ini-
tial HALT-C Trial protocol, patients who achieved
SVR ceased participation in the trial after Week 72,
although many of the patients continued to be fol-
lowed outside the HALT-C Trial by the investigators
at their respective sites. In 2008, the HALT-C Trial
protocol was amended to allow HALT-C Trial clinical
centers to contact patients who had achieved SVR and
invite them to participate in the current study. The
HALT-C Trial protocol amendment was approved by
the institutional review boards of all the HALT-C Trial
sites. Patients provided informed consent for participa-
tion in the initial HALT-C Trial as well as the
amended protocol.
The amended protocol allowed for a single study
visit consisting of a standard interview regarding the
occurrence of hepatic decompensation or a diagnosis
of HCC, and a physical examination to identify clini-
cal signs of hepatic decompensation. Blood was drawn
to test for complete blood count, hepatic panel, creati-
nine, INR, AFP, and HCV RNA, and an abdominal
ultrasound was performed. Patients who had a history
consistent with decompensated liver disease, HCC, or
liver transplantation were asked to sign a ‘‘release of
information’’ form to allow HALT-C Trial investigators
to review medical records related to the event. Patients
who agreed to participate but were unable to attend
an in-person clinic visit answered a structured tele-
phone interview designed to elicit evidence of decom-
pensated liver disease, HCC, or liver transplantation
and were asked to mail a signed release of medical
records to the clinical site to allow findings from a
recent physical examination, blood tests, and abdomi-
nal imaging (not performed at a HALT-C clinical site)
to be reviewed.
In order to assess the relative impact of achieving
SVR on morbidity and mortality, we selected two
comparison groups from the 1050 patients randomized
into the HALT-C Trial (Fig. 1). When selecting these
comparison groups, we excluded 237 patients enrolled
through the Express pathway because detailed informa-
tion on whether these patients were nonresponders or
breakthrough/relapsers to peginterferon and ribavirin
given outside of the HALT-C Trial was not available.
We also excluded 517 patients randomized to peginter-
feron maintenance in order to eliminate a potential
effect of maintenance peginterferon on clinical out-
comes, although we found no effect of maintenance
peginterferon on clinical outcomes in our prior analy-
sis.9 Of the remaining 333 nonresponders who were
randomized to the no-treatment (control) arm, 24
were excluded for the following reasons: 17 were not
followed after randomization, six were treated with
interferon outside of the HALT-C Trial, and one had
negative HCV RNA test results during the randomized
phase of the HALT-C Trial. Thus, the first comparison
Fig. 1. Flow diagram of HALT-C subjects included in the current
analysis. Of the 1145 patients entering the lead-in phase and receiv-
ing treatment with peginterferon alfa-2a at 180 lg/week and ribavirin
at 1-1.2 g/day, 180 achieved an SVR. Of these, 140 participated in
the current study (SVR group). A total of 813 patients from the HALT-C
lead-in phase and 237 patients who were nonresponders or relapsers
to peginterferon/ribavirin given outside of the HALT-C Trial (Express)
were randomized to either no treatment (control arm) or to peginter-
feron alfa-2a at 90 lg/week for 3.5 years, and then followed without
treatment. For the current analysis, we excluded all patients random-
ized to receive peginterferon at 90 lg/week in order to eliminate a
possible effect of long-term interferon on outcomes. Among the 533
patients randomized to no treatment, 120 patients from the Express
arm were excluded because data on whether the patients were NR or
BT/R were not available. Of the remaining 333 nonresponders in the
control arm, 24 were eliminated because they were not followed after
randomization (17 patients), received interferon treatment after ran-
domization (6 patients), or had undetectable HCV RNA during follow-
up (1 patient). Three of the 80 patients with BT/R were eliminated
because they were not followed after randomization (2 patients) or
received treatment with peginterferon (1 patient). FU, follow-up;
PegIFN, peginterferon.
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group consisted of 309 nonresponder patients random-
ized to the control arm of HALT-C Trial who were
viremic and did not receive subsequent interferon. The
second comparison group consisted of patients who
had a breakthrough or relapse and who were random-
ized to the control arm of the HALT-C Trial. Of the
80 patients in the BT/R group randomized to the con-
trol (untreated) arm, three were excluded for the fol-
lowing reasons: two were not followed after random-
ization, and one patient was treated with peginterferon
and ribavirin outside of the HALT-C Trial. Thus, a
total of 77 patients with BT/R who were randomized
to the control arm and who remained viremic after
randomization were included in this analysis.
The beginning date for this analysis was the day
when patients began peginterferon and ribavirin treat-
ment during the lead-in phase of the HALT-C Trial
(August 2000 to January 2003). The end date for
determination of clinical outcomes for the SVR
patients was the day of their amended protocol study
visit or telephone contact (September 2008 to March
2009). The date for assessment of blood tests for SVR
patients was the day of the amended protocol study
visit or the most recent laboratory tests from the
patient’s medical records (for patients participating by
telephone). For the NR and BT/R groups, clinical out-
come data were included for the first 7.5 years of par-
ticipation in the HALT-C Trial. The blood test results
from the Month 72 visit for the NR and the BT/R
groups were used for analysis of changes in blood tests
because a larger number of patients had reached that
time point (239 of 386) compared with the number
available at the Month 84 visit (144 of 386). The me-
dian follow-up time for patients in the SVR group was
86 months, patients in the BT/R group was 85
months, and patients in the NR group was 79 months.
Follow-up rates through Month 72 were 60% (185/
309) in the NR group and 70% (54/77) in the BT/R
group. The survival status of all patients was evaluated
by searching the online U.S. Social Security Death
Index (SSDI) (http://ssdi.rootsweb.ancestry.com),
which is generated from the U.S. Social Security
Administration’s Death Master File. The SSDI search
of patients in the SVR group was undertaken in
March 2009; for patients in the BT/R and NR groups,
the SSDI search was performed in October 2009.
Assessment of Clinical Outcomes. Clinical out-
comes were predefined in the HALT-C Trial protocol
and included death due to any cause, liver-related
death, HCC, and hepatic decompensation (ascites, he-
patic encephalopathy, variceal hemorrhage, or sponta-
neous bacterial peritonitis); we also collected data on
liver transplantation. Two definitions of HCC were
adopted in the HALT-C Trial: ‘‘definite’’ HCC and
‘‘presumed’’ HCC. Definite HCC was defined by his-
tologic confirmation or a new, 2-cm mass lesion on
imaging with AFP levels increasing to >1000 ng/mL.
Presumed HCC was defined as a new mass lesion on
ultrasound in the absence of histology and AFP <
1000 ng/mL in conjunction with one of the following
characteristics: (1) two liver imaging studies showing a
mass lesion with characteristics of HCC, (2) progres-
sively enlarging lesion on ultrasound and leading to
death, or (3) one additional imaging study showing a
mass lesion with characteristics of HCC that either
increased in size over time or was accompanied by
increasing AFP levels.11 An outcome committee, whose
members consisted of a rotating panel of three clinical
site investigators blinded to study participant and clini-
cal site, reviewed and adjudicated the validity of each
clinical outcome.
For the current analysis, we assessed overall mortal-
ity (i.e., death from any cause) or liver transplantation,
and liver-related morbidity and mortality. Death from
any cause or liver transplantation was defined as any
patient who died (of any cause) or had undergone liver
transplantation. The four categories of liver-related
morbidity and mortality were: (1) Any liver-related
clinical outcome: all patients in whom decompensated
liver disease (ascites, variceal bleeding, hepatic ence-
phalopathy, or spontaneous bacterial peritonitis) or
HCC (presumed or definite) developed, or who had
undergone liver transplantation, or died from condi-
tions related to liver disease. For the calculation of the
cumulative incidence of any liver-related outcomes,
patients were censored at the time when the first out-
come developed. (2) Decompensated liver disease: all
patients whose first clinical outcome was decompen-
sated liver disease. (3) HCC: all patients in whom, at
any time during the study, definite or presumed HCC
developed. (4) Liver-related death or liver transplanta-
tion: any patient who died as the result of a liver-
related cause, based on the opinion of the clinical site
principal investigator, or who had undergone liver
transplantation.
Statistical Analyses. Statistical analyses were per-
formed at the Data Coordinating Center (New Eng-
land Research Institute, Watertown, MA) with SAS
software, release 9.1 (SAS Institute Inc., Cary, NC).
The chi-squared and analysis of variance tests were
used to determine categorical and continuous variables
that were significantly different between the SVR
group and the two comparison groups (NR and BT/
R). Cox proportional hazard regression models were
836 MORGAN ET AL. HEPATOLOGY, September 2010
used to evaluate the association between risk factors
and each of the five outcomes. Data were censored at
the patient’s last follow-up visit or at 7.5 years after a
patient began peginterferon and ribavirin treatment,
whichever occurred first. Variables with a P value
<0.05 on univariate analysis and variables reported
previously to be associated with outcomes were entered
into multivariate analyses for each of the five clinical
outcomes. One multivariate model was created for
each of the five outcomes, and the adjusted cumulative
incidence rates for each of the five outcomes were cal-
culated by adjusting for risk factors that were signifi-
cant on multivariate analyses. Adjusted cumulative
rates were compared at the means of the covariates for
each group.
Routine blood tests used to assess disease severity in
patients with chronic hepatitis C were compared at
three time points: (1) baseline (entry into the lead-in
phase of the HALT-C Trial), (2) approximately 18
months after baseline (Week 72 visit for SVR patients;
Month 18 visit for BT/R and NR patients), and (3)
approximately 72-84 months after baseline (amended
protocol study visit for SVR patients; Month 72 visit
for BT/R and NR patients). Paired t tests were used to
compare means of baseline and follow-up laboratory
tests between different time points in each group.
Results
Demographic and Clinical Data. Data were
obtained on 140 (78%) of the 180 HALT-C Trial
patients who achieved SVR. Thirty patients could not
be located, and 10 declined to participate. The 40
patients who did not participate did not differ from
the 140 who did at baseline or at Week 72 in demo-
graphic characteristics, baseline Ishak fibrosis score, or
routine blood tests. Specifically, at Week 72 no differ-
ence was found between the SVR nonparticipants (n
¼ 40) and participants (n ¼ 140) for key predictors
of clinical outcome such as age (49.8 6 8.02 years
versus 50.0 6 6.12 years for nonparticipants and par-
ticipants, respectively; P ¼ 0.87), albumin (4.3 6 0.4
versus 4.2 6 0.4 g/dL; P ¼ 0.26), platelet count (191
6 56 versus 191 6 59  1000/mm3; P ¼ 0.97), AFP
(3.3 6 1.5 versus 3.3 6 1.7 ng/mL; P ¼ 0.88) or
alkaline phosphatase (72 6 20 versus 78 6 20 IU/
mL; P ¼ 0.27). Three of the 140 SVR patients had
died, and copies of death certificates for two of the
three were obtained. Of the 137 surviving participants,
70 were seen in clinic whereas 67 were evaluated by
telephone interviews supplemented by examination of
external medical records. None of the 30 patients with
SVR who could not be located were listed as deceased
in the online SSDI.
Baseline demographic data as well as clinical and
laboratory data on the SVR group and the two com-
parison groups (BT/R and NR) are shown in Table 1.
The three groups differed significantly in race/ethnic-
ity, presence of cirrhosis, hepatitis C genotype, and
laboratory values associated with advanced liver dis-
ease. SVR patients were more likely to be Caucasian,
infected with HCV genotypes other than 1, to have fi-
brosis (rather than cirrhosis) on baseline biopsy and
less likely to have laboratory values associated with
advanced liver disease (e.g., low blood counts and al-
bumin, or high INR and AFP) compared with patients
in the BT/R and NR groups.
Durability of SVR. Ninety-one SVR patients had
follow-up HCV RNA testing performed an average of
78.6 6 15.9 months (range: 22.1-99.6 months) after
achieving SVR, and 90 of the 91 (99%) had undetect-
able HCV RNA in serum. The patient with reappear-
ance of HCV RNA was presumed to have a relapse
because there were no risk factors for reinfection and
genotype 1b was detected at enrollment and at HCV
reappearance 15 months following discontinuation of
combination treatment. This patient had persistently
detectable HCV RNA but no evidence of hepatic
decompensation or HCC when last seen 108 months
after enrollment in the lead-in phase of the HALT-C
Trial.
Clinical Outcomes of SVR Patients. Five patients
who achieved SVR (3.6%) had six liver-related clinical
outcomes (Table 2). One patient (patient A) had a
3-cm lesion detected on ultrasound performed for his
amended study clinic visit, 7.3 years after his baseline
visit and 5.8 years after achieving SVR. At entry into
the HALT-C Trial, he had a liver biopsy with an Ishak
fibrosis score of 4 and his platelet count was 112,000/
mm3. The resected specimen revealed a well-differenti-
ated HCC; cirrhosis was present in the nontumor
liver. Another patient (patient B) who had an Ishak fi-
brosis score of 3 on his baseline liver biopsy was found
to have a 15-cm lesion on magnetic resonance imaging
performed to evaluate an elevated AFP during a rou-
tine follow-up visit 5.8 years after his baseline visit and
4.4 years after achieving SVR. Biopsy of the lesion
confirmed the presence of HCC and cirrhosis in the
adjacent liver. This patient died of progressive HCC 4
months later. After magnetic resonance imaging was
performed, a third patient (patient G) was found to
have a 1.3-cm liver mass and underwent transarterial
chemoembolization twice, followed by liver transplan-
tation, but no tumor was found in the liver explant.
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This patient did not meet the HALT-C Trial criteria
for presumed or definite HCC. Two patients with
SVR experienced variceal hemorrhage (patients E
and F).
Two additional SVR patients died, one from alcohol
toxicity (patient D) and the other from an uncon-
firmed cause, although a family member reported that
the death had occurred after spinal surgery (patient









A Fibrosis HCC 7.29 55 Male 3.0 cm mass detected by US at SVR study visit.
Cirrhosis and HCC present in resected liver.
B Fibrosis HCC 5.80 50 Male 15 cm mass detected by MRI after elevated AFP noted
during routine clinic visit. Cirrhosis and HCC present
in liver biopsy. Died of HCC.
Death (Liver-related) 6.14
C Fibrosis Death (Non–liver related or Unknown) 5.59 63 Female Death of unknown cause. Family member reported the
death occurred following spinal surgery.
D Fibrosis Death (Non–liver related) 3.03 49 Male Death due to alcohol toxicity.
E Fibrosis Variceal hemorrhage 4.13 47 Male Comorbidities: obesity and diabetes.
F Fibrosis Variceal hemorrhage 3.27 46 Male Comorbidities: return to heavy alcohol use
G Cirrhosis Liver transplant 7.30 47 Male 1.3 cm mass in liver on MRI. Treated with TACE twice.
Liver transplant 4 months after 2nd TACE did not show HCC.
*The race/ethnicity of the seven patients was non-Hispanic white.
Table 1. Baseline Demographic, Clinical, and Laboratory Data for Patients in the SVR, BT/R, and NR Groups
Variable
SVR Group (n 5 140) BT/R Group (n 5 77) NR Group (n 5 309)
P Value*N or mean % or SD N or mean % or SD N or mean % or SD
Age (years) 48.6 6.1 48.6 5.7 49.6 7.6 0.23
Sex
Male 107 76.4% 57 74.0% 215 69.6% 0.30
Female 33 23.6% 20 26.0% 94 30.4%
Race/ethnicity
White 112 80.0% 62 80.5% 209 67.6% 0.001
Black 8 5.7% 3 3.9% 61 19.7%
Hispanic 15 10.7% 10 13.0% 28 9.1%
Others 5 3.6% 2 2.6% 11 3.6%
Stratum
Fibrosis 111 79.3% 53 68.8% 177 57.3% <0.0001
Cirrhosis 29 20.7% 24 31.2% 132 42.7%
Ishak fibrosis score 3.6 1.2 3.9 1.2 4.2 1.3 <0.0001
Steatosis score 1.2 0.88 1.1 0.96 1.4 0.84 0.02
Genotype 1
Yes 101 72.1% 65 85.5% 291 94.5% <0.0001
No 39 27.9% 11 14.5% 17 5.5%
Genotype 3
Yes 14 10.0% 5 6.6% 8 2.6% 0.004
No 126 90.0% 71 93.4% 300 97.4%
Body mass index 29.3 5.5 29.4 5.3 30.2 5.7 0.16
WBC  1000/mm3 6.17 2.1 5.98 1.98 5.62 1.73 0.01
Hemoglobin, g/dL 15.5 1.35 15.1 1.43 14.9 1.38 0.001
Platelet count x1000/mm3 180.2 59.2 180.7 55.8 164.2 70.5 0.02
Creatinine, mg/dL 0.85 0.14 0.85 0.16 0.84 0.17 0.62
AST, U/L 89.1 54.1 93.6 76.5 89.2 57.9 0.83
ALT, U/L 137.5 83.5 132.2 112.9 112.0 79.6 0.008
Alkaline phosphatase, U/L 88.3 36.8 87.8 31.7 102.3 47.8 0.001
Total bilirubin, mg/dL 0.74 0.34 0.79 0.40 0.78 0.36 0.45
Albumin, g/dL 4.04 0.37 3.94 0.34 3.84 0.39 <0.0001
INR 1.02 0.09 1.02 0.09 1.04 0.11 0.04
AFP, ng/mL 7.9 14.2 7.70 10.6 18.2 27.5 <0.0001
*P value for comparison of the three groups.
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C). These two deaths were not considered to be liver-
related.
Models to Predict Clinical Outcomes. The num-
bers of patients with death from any cause/liver trans-
plantation and with liver-related outcomes in the SVR,
BT/R, and NR groups are presented in Table 3. SVR
patients had fewer deaths from any cause/liver trans-
plantation (four or 2.9%) and liver-related outcomes
(six outcomes in five [3.6%] patients) compared to
BT/R (four or 5.2%) death from any cause/transplant;
15 liver-related outcomes in eight (10.4%) patients
and NR (64 or 20.7%) death from any cause/trans-
plant; 148 liver-related outcomes in 78 (25.2%)
patients. Because the three patient groups differed in
baseline severity of liver disease (e.g., Ishak fibrosis
score, platelet count, albumin level; Table 1), we per-
formed a Cox proportional hazard regression analysis
(Table 4), adjusting for histological stratum (fibrosis or
cirrhosis), age, race, platelet count, AST/ALT ratio,
albumin, alkaline phosphatase, AFP, and treatment
response (SVR, BT/R, and NR). These variables were
selected because they have been associated with liver
disease severity or clinical outcomes in prior HALT-C
Trial analyses.11,12 Separate multivariate models were
developed to assess risk factors associated with the five
outcomes analyzed in this study.
A low baseline platelet count was significantly asso-
ciated with all five outcomes, whereas a low baseline
albumin was a significant risk factor for all outcomes
except HCC (Model 4). Age and baseline alkaline
phosphatase were also significant risk factors for the
development of HCC (Model 4). Achieving an SVR,
when compared with nonresponders, was associated
with a significantly lower hazard ratio for each of the
Table 3. Number of Events and Patients With Death From Any Cause, Liver-related Death, Liver Transplantation,
Decompensated Liver Disease or HCC in the SVR, BT/R, and NR Groups
Clinical Outcomes* n (%) SVR Group (n 5 140) BT/R Group (n 5 77) NR Group (n 5 309)
Death (any cause) or liver transplantation 4 (2.9%) 4 (5.2%) 64 (20.7%)
Death (any cause) 3 (2.1%) 2 (2.6%) 37 (12.0%)
Liver transplantation 1 (0.7%) 2 (2.6%) 34 (11.0%)
Decompensated liver disease (total) 2 (1.4%) 5 (6.5%) 43 (13.9%)
Variceal hemorrhage 2 (1.4%) 2 (2.6%) 12 (3.9%)
Ascites 0 3 (3.9%) 31 (10.0%)
Spontaneous bacterial peritonitis 0 0 3 (1.0%)
Hepatic encephalopathy 0 1 (1.3%) 19 (6.1%)
HCC (definite or presumed) 2 (1.4%) 5 (6.5%) 28 (9.1%)
Liver-related death or liver transplantation 2 (1.4%) 4 (5.2%) 49 (15.9%)
Liver-related death 1 (0.7%) 2 (2.6%) 21 (6.8%)
Death from any cause or liver transplantation: 4 outcomes (4 patients) 4 outcomes (4 patients) 71 outcomes (64 patients)
Liver-related outcomes:
Total no. of outcomes 6 outcomes (5 patients) 15 outcomes (8 patients) 148 outcomes (78 patients)
(Total no. of patients*)
*Patients can be counted more than once.
Table 4. Cox Proportional Hazard Analysis for Death From Any Cause or Liver Transplantation (Model 1),
and for Liver-related Morbidity and Mortality (Models 2-5)
Variables
Model 1 Death (Any
Cause) or Liver
Transplantation


















HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Age (per 1 year) 1.05 1.01-1.10
Baseline platelets (per 10,000/mm3) 0.88 0.83-0.92 0.85 0.81-0.89 0.86 0.80-0.92 0.85 0.79-0.92 0.86 0.81-0.92
Baseline albumin (per 0.1 g/dL) 0.89 0.83-0.94 0.91 0.87-0.96 0.90 0.83-0.96 0.88 0.83-0.95
Baseline alkaline phosphatase (per 10 U/L) 1.08 1.02-1.13
Baseline AFP (per 10 ng/mL) 1.06 1.01-1.12
Treatment response
BT/R vs. NR 0.29 0.10-0.79 0.46 0.22-0.96 0.57 0.22-1.46 0.96 0.36-2.54 0.43 0.15-1.21
SVR vs. NR 0.17 0.06-0.46 0.15 0.06-0.38 0.13 0.03-0.53 0.19 0.04-0.80 0.12 0.03-0.48
The following variables were not significant in any model: race, stratum (fibrosis versus cirrhosis), and AST/ALT ratio.
HR, hazard ratio.
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five clinical outcomes. Patients with BT/R had a sig-
nificantly lower hazard ratio for death from any cause/
liver transplantation (hazard ratio [HR] ¼ 0.29; 95%
confidence interval [CI] ¼ 0.10-0.79) and for any
liver-related outcome (HR ¼ 0.46; 95%CI ¼ 0.22-
0.96) when compared with NR. Fibrosis stage, race,
and baseline AST/ALT ratio were not statistically sig-
nificant risk factors in any multivariate model.
Adjusted Rates of Clinical Outcomes in SVR,
BT/R, and NR Patients. The cumulative rates of
death from any cause/liver transplantation, and of
liver-related morbidity and mortality, adjusted for the
significant risk factors identified in the Cox models,
are shown in Fig. 2 and Supporting Information Table
1. At year 7.5 from enrollment, the adjusted cumula-
tive incidence of outcomes for the SVR, BT/R, and
NR patients was, respectively, 2.2%, 4.4%, and 21.3%
for death from any cause or liver transplantation (P ¼
0.0002); 2.7%, 8.7%, and 27.2% for any liver-related
outcome (P < 0.0001); 0.9%, 4.7%, and 11.7% for
decompensated liver disease (P ¼ 0.012); 1.1%, 5.5%,
and 8.8% for HCC (P ¼ 0.077); and 0.99%, 4.1%,
Fig. 2. Cumulative proportion of patients with death from any cause or liver transplantation, or with liver-related clinical outcomes, during 7.5
years for patients with SVR, BT/R, and NR, adjusted for variables that were significant in the Cox proportional hazard analysis. (A) Death from
any cause or liver transplantation, (B) any liver related outcome, (C) decompensated liver disease, (D) HCC, and (E) liver-related death or liver
transplantation.
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and 14.7% for liver-related death or liver transplanta-
tion (P ¼ 0.005). For each of the five outcomes, the
adjusted cumulative proportion of patients with out-
comes was lowest for the SVR group, intermediate for
the BT/R group, and highest for the NR group of
patients. Although the SVR patients had fewer out-
comes than the BT/R patients, the adjusted cumulative
incidence was not significantly different between the
SVR and the BT/R groups for any of the five out-
comes (SVR versus BT/R: P ¼ 0.44 for death or
liver transplantation, P ¼ 0.05 for any liver-related
outcome, P ¼ 0.07 for decompensated liver disease,
P ¼ 0.05 for HCC, and P ¼ 0.13 for liver-related
death or liver transplantation). The adjusted cumula-
tive proportion with death or liver transplantation (P
¼ 0.02) or any liver-related outcome (P ¼ 0.04) was
significantly lower for the BT/R group when com-
pared with patients from the NR group, but the dif-
ference between these two groups was not statistically
significant when decompensated liver disease (P ¼
0.24), HCC (P ¼ 0.93), or liver-related death or
liver transplantation (P ¼ 0.11) were analyzed
individually.
Because there was no effect of long-term peginter-
feron treatment on the rate of clinical outcomes,9 the
Cox proportional hazard analysis and the adjusted cu-
mulative survival analysis were repeated after including
400 patients who were randomized to the peginterferon
alfa-2a (90 lg/week) arm of the HALT-C Trial and who
were followed after randomization. Including these
patients increased the NR group to 638 and the BT/R
group to 148 individuals. All HRs and cumulative out-
come analyses were essentially unchanged, except that
statistical significance for SVR versus NR was stronger,
the HR and adjusted survival analyses for SVR versus
BT/R were significant for any liver-related outcome (P
< 0.05), and the HR and adjusted survival analyses for
BT/R versus NR were significant for liver-related death
or liver transplantation (P < 0.05) (data not shown).
Changes in Laboratory Test Results. Figure 3
shows changes in selected blood tests over time among
patients who had blood tests performed at each of the
three time points. Among the SVR patients, platelet
count and albumin (shown in Fig. 3) as well as AST,
ALT, and AFP (data not shown) significantly improved
from baseline to the most recent values. A significant
Fig. 3. Mean (6 standard error of the mean) value of laboratory tests at baseline, Month 18 (M18), and Month 72/84 (M72/M84) for
patients with SVR, BT/R, and NR. (A) Platelet count (1000/mm3) (n ¼ 100 [SVR], 54 [BT/R], and 181 [NR]). (B) Serum albumin (g/dL)
(n ¼ 102 [SVR], 54 [BT/R], and 184 [NR]). (C) Serum total bilirubin (mg/dL) (n ¼ 102 [SVR], 54 [BT/R], and 184 [NR]). (D) INR (n ¼ 85
[SVR], 54 [BT/R], and 179 [NR]). Statistical comparisons within each group are between two adjacent time points (i.e., baseline versus M18
and M18 versus M72/M84). *P < 0.05; **P < 0.001; þP < 0.0001.
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improvement in platelet count and albumin was also
observed between Week 72 (Month 18), when SVR was
attained, and the time of the amended study visit. In
contrast, patients from the BT/R and NR groups had a
significant worsening of platelet count and bilirubin
between baseline and Month 72 visits, and NR patients
also had deterioration in albumin and INR during the
same time period.
Discussion
We report here the results of a prospective, long-term
follow-up study to evaluate the effect of achieving SVR
with pegylated interferon and ribavirin treatment on
death from any cause or liver transplantation, and on
liver-related morbidity and mortality, in a large cohort
of patients in the United States with chronic hepatitis C
and bridging fibrosis or cirrhosis. Patients who achieved
SVR were compared with two groups of patients who
were enrolled into the HALT-C Trial at the same time:
(1) patients who failed to respond to peginterferon and
ribavirin (NR) and (2) patients with virologic clearance
at Week 20 but subsequent virologic breakthrough dur-
ing combination antiviral therapy or relapse after com-
pletion of therapy (BT/R). In this cohort of patients
with advanced chronic hepatitis C, we found that those
who achieved SVR after peginterferon and ribavirin
treatment had a significantly reduced risk of death from
any cause/liver transplantation, and of liver-related mor-
bidity and mortality, when compared with patients in
the NR group. Importantly, achieving SVR significantly
reduced the risk of developing each component of liver-
related morbidity and mortality (i.e., hepatic decom-
pensation, HCC, and liver-related death or liver trans-
plantation) when compared with NR patients.
A strength of this study was the long duration of
prospective follow-up. Patients were identified at entry
into the HALT-C Trial and were followed for a me-
dian of 79 (NR) to 86 (SVR) months after starting
their final course of peginterferon/ribavirin. Our find-
ings on the effect of SVR on liver-related clinical out-
comes are similar to those of retrospective, and often
smaller, studies from Japan5,7,13-15 and Europe,6 the
results of which supported an approximately 70%-
90% reduction in the risk of liver-related clinical out-
comes over a follow-up period of 2-6 years in patients
achieving an SVR. An interesting observation in our
study was the relative rapidity of the effect of achieving
an SVR on hepatic decompensation; within 1 year,
rates of decompensation among patients with an SVR
and those with NR began to diverge. Both SVR
patients in whom HCC developed had no discernable
cause for ongoing liver damage. These data underscore
the continued risk of HCC in patients with advanced
chronic hepatitis C, even in those who achieved SVR,
as has been noted previously.2,4,7-8,13 Because both
SVR patients in whom HCC developed were diag-
nosed more than 4 years (4.4 and 5.9) after achieving
SVR, HCC surveillance should continue for more
than 5 years after SVR, and probably for life.
Based on Cox proportional hazard analyses, we found
that baseline platelet count was associated independently
with all five outcomes, whereas albumin level was associ-
ated independently with four outcomes (not with
HCC). Age and alkaline phosphatase were associated
with the risk of HCC but not with any other outcome.
This observation could suggest that the development of
HCC follows a different pathway than, and is tempo-
rally independent of, the development of other compli-
cations of liver disease. In prior studies, age and sex have
been associated with risk of HCC, and we reported pre-
viously that alkaline phosphatase is associated with the
risk of HCC in the HALT-C Trial cohort.11
An interesting and heretofore unreported finding was
the intermediate risk of clinical outcomes in the BT/R
group, between the risk of that for the NR and the SVR
groups. In particular, the adjusted risk of death from
any cause/liver transplantation or of any liver-related
outcome was significantly lower in the BT/R group
than in the NR group. The risks of decompensated liver
disease, HCC, and liver-related death or liver transplan-
tation were also lower in the BT/R group than in the
NR group, although these differences did not reach sta-
tistical significance. These findings suggest that com-
plete viral suppression is associated with a reduced risk
of clinical outcomes and that the benefits may outlast
the period in which HCV RNA is undetectable.16
Laboratory tests commonly associated with liver dis-
ease severity, such as albumin and platelet count,
improved in patients achieving an SVR but worsened in
patients not achieving SVR. Of particular interest, in
these patients with advanced fibrosis who achieved SVR,
platelet count and albumin continued to improve
between Week 72 and the final visit approximately 5.5
years later. In the only prior report of laboratory tests
among SVR patients followed for 5 years, George et al.2
were unable to demonstrate improvement in laboratory
tests. Therefore, improvement in liver-related blood
tests after achieving an SVR in patients with advanced
fibrosis is an original finding. One possible explanation
for the difference between the prior report and ours is
that the majority of patients followed by George and
colleagues2 had mild liver fibrosis, with minimal
changes in albumin and platelets that would not be
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expected to improve during follow-up monitoring.
Overall, our data demonstrating improvement in liver-
related blood tests, when combined with prior studies
demonstrating reduction in liver fibrosis,1-3 suggest that
liver function continues to recover in the years following
an SVR in patients with advanced fibrosis/cirrhosis.
This study has several limitations. A total of 17% of
patients who achieved SVR were lost to follow-up and
an additional 6% declined to participate. Potentially,
decompensated liver disease or HCC may have devel-
oped in these patients; therefore, our results may be an
underestimate of the rate of clinical outcomes in
patients who achieved SVR. We were able to determine,
however, that none of the 30 patients who were lost to
follow-up died according to a search of the SSDI per-
formed at the end of amended study. Another potential
limitation was the fact that the patients who achieved
SVR were not monitored as closely as the BT/R and
NR patients and that not all SVR patients were eval-
uated in person. Nevertheless, medical records with
physical examination, blood tests, and/or liver imaging
of the patients who were interviewed by phone were
reviewed and added reliability to the ascertainment of
the occurrence of decompensated liver disease or HCC
as of the time of their last follow-up assessment.
In summary, we found that patients with advanced
chronic hepatitis C who achieved SVR had significantly
lower rates of death from any cause or liver transplanta-
tion, and of liver-related morbidity and mortality, com-
pared to patients who failed to eliminate HCV with
treatment (NR). Still, patients who achieved SVR
remained at risk of HCC for at least 6 years after achiev-
ing SVR. Our study also showed that patients who had
temporary, but complete viral suppression (BT/R) were
less likely to die or undergo liver transplantation, or to
experience liver-related complications than patients in
the NR group, indicating that the duration of clinical
benefit may outlast the period of actual viral suppres-
sion. Importantly, laboratory tests associated with liver-
disease severity (e.g., platelet count, albumin) continued
to improve after patients achieved SVR. Overall, our
data indicate that patients with chronic hepatitis C and
advanced hepatic fibrosis who achieve SVR have a
marked reduction in the risk for death or liver transplan-
tation, or of liver-related complications, and continued
improvement in laboratory markers of liver function in
the 5-6 years following successful viral eradication.
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